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ABSTRACT 
 
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma type, and 
comprises nearly 500 newly diagnosed cases in Sweden every year. DLBCL is a group of 
aggressive lymphomas that are extremely heterogeneous and differ in morphology, 
immunophenotype, molecular and clinical features as well as in response to therapy. The 
transformation of low malignant lymphoma, most commonly follicular lymphoma (FL), to 
DLBCL is associated with a progressive disease and poor prognosis. The overall aim of this 
thesis was to identify the genetic events underlying the progression and transformation of 
indolent FL to aggressive DLBCL and to outline molecular alterations distinguishing DLBCL 
with germinal center (GC) and non-GC phenotype.  
In search for novel markers in lymphoma, we have investigated an anti-apoptotic protein, 
HS-associated protein X-1 (HAX-1), at the protein and transcript level in malignant 
lymphomas (paper I). We found high levels of HAX-1 mRNA and protein expression in B-
cell lymphomas. We also identified a positive association between proliferation (Ki67) and 
HAX-1 expression, as well as an inverse correlation between Bcl-2 and HAX-1 demonstrated 
on a transcript and protein level in FL, which indicates the potential role of HAX-1 as a Bcl-2 
homolog. In papers II and III we studied paired tumours of FL and its transformed DLBCL 
(tDLBCL) counterparts and compared with de novo DLBCL (dnDLBCL) using array-
comparative genome hybridisation (array-CGH) in order to outline genetic alteration of 
importance for the transformation process. We identified a gain of 2p15-16.1 as a potential 
prognostic marker, and that this alteration may appear already in the FL prior to 
transformation. This chromosomal region encompasses, among others, genes involved in NF-
κB pathway, such as REL, USP34, COMMD1, OTX1 and of known importance for B-cell 
development, such as BCL11A. We have also performed whole exome sequencing (WES) 
results in a smaller group of patients with consecutive lymphoma samples. A comparison 
with array-CGH data showed that these two methods complement and strengthen each other 
in pinpointing crucial genetic events. Furthermore, our studies revealed that clonal evolution 
of transformed tumours occurs according to the branching model. A number of mutations 
identified in the peri-transformation phases – defined as FL appearing prior and tDLBCL 
directly after transformation - affected genes involved in histone modifications, cell cycle, 
apoptosis, PI-3 kinase pathway, and Ras signalling pathway. In Paper IV we performed 
proteomic profiling of DLBCL subtypes i.e. non-GC and GC, and identified 91 proteins 
present exclusively in the non-GC type of DLBCL. We focused on two proteins of 
importance for the NF-κB pathway (BiP and Hsp90) as well as on Cyclin B2. We observed 
increased expression of these three proteins in DLBCL and also in non-GC vs GC type of 
DLBCL. These findings suggest a potential relevance of these proteins as prognostic markers 
and may lead to new treatment options. 
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INTRODUCTION 
  
1 INTRODUCTION 
 
1.1 TUMOUR GENETICS 
It is generally believed that tumourigenesis in humans is a multistep process and that the 
genetic alterations stepwise drive the progressive evolution of normal cells into malignant 
ones (Figure 1). Pathological observations reveal the lesions that represent intermediate steps 
during progressive development from normal cells to malignant cancer. Genetic analysis also 
shows that the genome of tumour cells are altered by both subtle mutations and obvious 
changes in chromosomes (1).  
 
Figure 1. Tumour progression is a stepwise process. Cancer arises through accumulation of 
genetic alterations, copy number changes and mutations. A combination of selected 
mutations defines the phenotype of the tumour cells. 
 
Historically, the genetic damage was divided into two kinds:  a dominant one, affecting genes 
named as “proto-oncogenes” and recessive one, referring to tumour suppressor genes. The 
first ones are usually associated to gain of function while the latter ones are typically affected 
by loss of function (2).  
These terms rather reflect the historical background related to the genes discovery than their 
normal function (2). 
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1.1.1 ONCOGENES  
What does make a gene an oncogene? And when a good guy turns bad… 
Proto-oncogene can be any gene that normally encodes proteins responsible for cell growth, 
differentiation and proliferation. In this category we can find growth factors with their 
receptors, signal transducers, transcription factors and regulators of apoptosis. The 
”activation” of a protooncogene into an oncogene is a pathological process resulting into 
increased growth and proliferation leading to tumourigenesis (2, 3).  
This ”activation” can occur through different mechanisms, typically involving bp mutations, 
amplifications or chromosomal rearrangements. 
Malignant transformation is related to “dominant” effect of protooncogene activation over 
normal cells, where ”evil overrides good”. However it may be restrained in two manners. 
Firstly, limitation is a threshold below which gene expression had very little or no 
consequence. Secondly, the effect of expression of an oncogene may be modulated by other 
proteins (2).  
 
1.1.2 TUMOUR SUPPRESSOR GENES  
“The guardians of the genome” 
Tumour suppressor genes are the guardians of the genome, involved in control of crucial 
activities in cell life such as DNA repair, cell cycle control and apoptosis.  They regulate 
protein degradation, cell specification, differentiation, migration and angiogenesis (3). 
Tumour suppressor genes can be divided in two groups: gatekeepers and caretakers. 
Caretaker genes act as protectors of the genome against damage, gatekeepers inhibit growth 
by inducing cell death and cell cycle arrest of already damaged cells (4).  
Thus, caretakers are not regulating cell proliferation but rather increase the genome stability. 
It has been suggested that increased activity of caretaker genes is important for genome 
stability and reduces cancer risk as well as postpone aging (4).  
Inactivation of caretakers often leads to cancer cell development. Our genome is constantly at 
risk of acquiring mutations, which can be caused by exposure to products of cell metabolism 
like reactive oxygen species or environmental chemical factors. Despite protecting 
mechanisms like antioxidant defense system, the cell will be still at risk to accumulate DNA 
damage. That is where DNA repair systems play crucial roles (4-6).   
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1.1.3 DNA REPAIR GENES 
There are a number of lesions in the DNA acquired by one or both strands that can be 
repaired by base or nucleotide excision repair. DNA double strand breaks can be repaired by 
nonhomologous endjoining or homologous recombination. Other lesions like mismatches and 
crosslinks are repaired by mismatch and crosslink repair genes, respectively (4). 
The genes responsible for coordination of these processes with activation of cell cycle 
checkpoints such as ATM and BRCA1/BRCA2 are also well known caretakers (4).  
Inactivation of DNA repair system within tumour cells, results in genetic instabilty, 
accompanied usually with loss or gains of partial or complete chromosomes. Different types 
of instability are the result of disorganisation in different repair systems (4).  
Within the category of gatekeepers, the TP53 gene is the most known. TP53 regulates the 
expression of genes responsible for apoptosis, cell cycle, DNA repair and angiogenesis (7). 
TP53 is also the most frequently mutated gene in human cancer. About half of tumours show 
alteration in TP53 alleles (8).   
The path to discovery of the TP53 as tumour supressor gene was filled with a few twists and 
turns (3) as TP53 was initially regarded as a dominant oncogene, due to its ability to 
transform cells in culture (9, 10). We know now, that these first experiments detected mutant 
p53, called dominant negative effect, creating a situation where a heterozygous mutation in 
TP53 causes a deficiency in the function of this gene, mimicking the effect of homozygous 
mutation in tumour supressor gene. It took a few years until Finlay and coworkers (1988) 
demonstrated that p53 acts as a suppressor of transformation (11).  
Backing up in time, the cardinal features of tumour suppression were first shown in studies 
on retinoblastoma and Wilms tumour before p53 was identified. Alfred Knudson’s legendary 
”two hit mutation theory” was a result of his perspective and work as pediatrician (12), 
(Knudson 1971). He postulated that retinoblastoma might be caused by two mutations; one 
inherited (germline) and one acquired. Thus children who inherited an affected gene, 
developed disease earlier in life and it affected both eyes. In non-hereditary cases, requiring 
two de novo mutations, the disease would be rare, develop later and would be unilateral.   
Inactivation of a tumour suppressor gene and loss of its normal function can be a result of 
different changes including large chromosomal alterations, mutations and epigenetic 
modifications.  
 
1.2 EPIGENETICS 
Pathological epigenetic changes are alternatives to mutations and chromosomal aberrations in 
disrupting gene functions (13).  
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Historically, the word ”epigenetics” was used to describe events that could not be explained 
by genetics (14). Conrad Waddington who is believed to coin this term described epigenetics 
as ”the branch of biology which studies the casual interactions between genes and their 
products, which bring the phenotype into being” (Waddington, 1942).   
In 1957, Conrad Waddington proposed the concept of an epigenetic landscape to represent 
the process of cellular decision-making during development. At various points in this process 
(represented in the original picture by a ball) can take specific permitted trajectories leading 
to different outcomes (15). 
Genetic and epigenetic changes occur together in the development of cancer. Feinberg et al.  
proposed a three step model where the first event is an epigenetic disruption of a progenitor 
cell which triggers a population of cells with ability to grow. The second step involves an 
initiating mutation within the population of epigenetically disrupted progenitor cells at the 
beginning of cell growth. This is a first step in cancer development. The third step is genetic 
and epigenetic instability, associated with clonal tumour evolution (13, 16).  
Epigenetic changes involves changes of global DNA methylation patterns, such as chromatin 
alterations and loss of imprinting (13). Altered DNA methylation is a striking feature of 
tumorigenesis. Most CG dinucleotides are methylated on cytosine in human genome. (13).  
It has been suggested that hypomethylation is important in the earliest stages of tumorigenesis 
while hypermethylation is of greater importance for tumour progression. Epigenetic 
modifications in cancer are typically related to hypermethylation of promotor region of genes 
especially associated with tumour suppressive function. This leads to silencing of tumour 
suppressor genes and promotes tumourigenesis (13, 16-18). All the above described 
mechanisms apply also to lymphoma and other hematological malignancies.    
The nature of epigenetic lesions may be very variable. The abnormal cell may switch its 
epigenotype and silence normally active genes and activate the silent ones by methylation 
changes, histone modifications and chromatin proteins. Epigenetic lesions may involve 
alterations in heterochromatin pattern and changes of methylation in gene promoters (16).  
The chromosomal aberrations such as rearrangements and mutations can cause widespread 
chromatin disruption. One example is the MLL1, which is rearranged and also activated in 
acute leukemia and also in some B-cell lymphomas. It activates gene expression by 
methylation of H3K4 . Another example of epigenetic lesion is the increased expression of 
the EZH2 gene, observed in many tumours including lymphomas (19). 
Are the epigenetic changes a cause or consequence? 
It is widely discussed that epigenetic changes may be a result of gene expression alterations. 
Good evidence for causal argument would be if the constitutional epigenetic changes were 
linked with a increased cancer link. We know for example that LOI (lost of imprinting) of  
the IGF2 gene is significantly associated with increased risk for cancer in children with 
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Beckwith–Wiedemann syndrome. Conversely, we know that epigenetic alterations occur in 
normal tissue like for e.g. hypermethylation of p16 that occurs with aging in normal tissue of 
women with breast cancer. However, such alterations has been not shown to increase cancer 
risk (16).  
 
1.3 TELOMERES  
Each chromosomal end consists of long stretches of (TTAGGG)n tandem repeats composes 
the telomeres. Telomeres function is to protect chromosomal ends from erosion, fusions and 
rearrangements with other chromosomes. Telomeres shorten with every cell division because 
the DNA polymerase is unable to replicate these ends due to lack of templates. Telomerase 
are the enzyme complexes that are responsible for maintaining the telomeres in cells 
undergoing multiple divisions such as B- and T-cell lymphocytes. Also, cancer cells may 
activate these enzymes in order to take advantage of continuous cell division (20).  
 
1.4 CANCER CYTOGENETICS 
When, why and how do chromosomal aberrations arise? 
Tumourigenesis is a process associated with acquisition of specific genetic abnormalities, 
some resulting in activation of oncogenes and inactivation of suppressor genes that are 
essential for tumour formation. The acquisition of these changes is a multi-step process, 
where characterisation of primary and secondary aberrations is of a great interest (21). 
The primary aberrations are mostly found as the sole karyotypic abnormalities and refer to 
the first changes occuring in neoplastic cells, and are fundamental for the establishment of a 
neoplastic clone (21).  
The primary aberrations are seen in cells already carrying the primary alterations and thus 
never appear alone. They may even be so numerous in later disease-stages that they 
completely dominate the picture (21). Secondary aberrations are considered to be less specific 
than primary changes and depend on the primary aberration. They may occur during the 
disturbed mitotic process and sometimes may be facilitated by the primary aberration. This 
leads to a genetic diversity within a tumour, where different tumour subclones undergo 
evolutionary selection (21). The subclones with proliferative advantage expand gradually 
over less fitted subclones. During this dynamic process, the total tumour karyotype may 
evolve towards a greater or smaller complexity according to a divergent or convergent model. 
Numerous data suggest that this process may be monoclonal or oligoclonal at this early stage 
(21).  
The concept of the primary and secondary acquired chromosomal aberration refers to 
functional distinction where primary alterations are considered as more specific (like specific 
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gene rearrangements) and secondary aberrations are the result of large genomic imbalances 
(22). According to this theory, the large chromosomal abnormalities would always be 
secondary to the primary mutations. While primary and secondary alterations are by 
definition clonal, the terminology ”cytogenetic noise” is used for extensive but non-clonal 
abnormalities (23).  
The question remains whether the primary and secondary aberrations appear by chance in a 
random manner or there is a predilection of specific lesions (preferably primary 
abnormalities) to specific genomic sites. The hypothesis of randomly occurring alterations, 
that occur along the genome with following selection for the more ”evolutionary fit” clones 
with proliferative advantage, is a logical and possible explanation (21). However, it is also 
easy to believe that certain genomic rearrangements (especially the primary ones) may tend to 
occur in a certain genomic localisation and as a result of interaction between a carcinogenic 
agent and specific genomic site. This theory is supported by the fact that several toxic agents 
have been found to increase the risk of particular translocations and genetic abnormalities 
(21).  
Moreover, for the external agents, the internal factors play a role in origin of specific 
chromosomal alterations. The susceptibility and tolerance to DNA brakes are common 
feature of tumour cells, increasing the possibility of tumourigenic recombination and 
mutations (24). Common chromosomal fragile sites that are involved in formation of DNA 
breaks can be considered as predisposing factors for chromosomal rearrangements (21, 25) . 
One should not forget the role of the three-dimensional chromosome architecture within a 
nucleus, where the chromosomal localisation is quite well defined (26-28). That localisation 
affects the way that various chromosomal aberrations arise and DNA double strand breaks 
are probably involved in this process. Another logical requirement for chromosomal 
rearrangements is a physical proximity between breakpoint regions. Several loci recombined 
in specific translocations, such as BCR/ABL; t(9;22) in chronic myeloid leukemia, IGH/MYC; 
t(8;14), IGH/CCD1 ; t(11;14) and IGH/BCL2; t(14;18) in B-cell malignancies, are closely 
located in the corresponding normal cell types (21, 29) . However, this is not enough to 
explain the origin of all rearrangements. Another factor that may facilitate the illegitimate 
recombination is the shared sequence motifs at the chromosome breakpoints (30-33). 
Still a lot needs to be explained concerning why and how the chromosomal alterations occur. 
For the time being we tend to believe that the primary and secondary genetic aberrations arise 
as stochastic events (21).  
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1.5 THE GERMINAL CENTER 
”Everything comes at a price” 
Germinal centers (GC) are the histological structures dedicated to the generation and the 
selection of B-cells that produce high affinity antibodies (34, 35).  
B-cells originate from pluripotent stem cell in bone marrow and continue to differentiate until 
a functional B-cell receptor is expressed. After starting migration from bone marrow, B-cells 
encounter the antigen, that initiates further differentiation in a lymph node. In the lymph node 
B-cells are localised in the follicles, while T-cells are located in the interfollicular areas. 
Some follicles form germinal centers and these are involved in the selection of B-cells 
secreting high affinity antibodies (35). Antigen specific memory B-cells and plasma cells 
appear within 1 week after antigen encounter, which indicates that the GC reaction is 
remarkably efficient (36).  In the GC reaction, a naive B-cell is activated by antigen receptor 
stimulation from T helper cell and transforms into centroblast that proliferates in the ”dark 
zone” of the GC. The ”dark zone” is a place where B-cells undergo somatic hypermutation 
(SHM), where a single base-pair changes are randomly introduced (1x 10-3 bases per 
generation into the IgV regions) in order to select for immunoglobulin with higher affinity for 
a specific antigen (37). After proliferative expansion and SHM in the dark zone, B-cells move 
to the “light zone” and the morphological change from centroblast to centrocyte. Here their 
fate depends on other GC resident cells like T-cells and follicular dendritic cells (35).  In the 
light zone the B-cells are selected depending on their ability to bind antigen presented to them 
by follicular dendritic cells and T-cells. This process is a negative selection, where most B-
cells acquire deleterious mutations in the IgV regions and then undergo apoptosis. The cells 
with highest affinity are selected for further differentiation. A fraction of B-cells also 
switches Ig classes (from IgM and IgD to other classes) by isotype switch recombination. 
This process enables to produce antibodies with different effector functions due to replacing 
IGH constant C-region by a downstream C-region gene i.e. Cγ, Cα, Cε, which allows 
expression of IgG, IgA, IgE without loosing the specificity (38)   
The germinal center is also a place of the origin of most human B-cells lymphomas (35). 
Moreover, the same genetic mechanisms that are involved in the fundamental germinal center 
function are involved in lymphomagenesis.  
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Figure 2. Germinal center – a figure illustrating processes during B-cell differentiation. 
Abbr.: CC, centrocyte; CB, centroblast; DZ, dark zone. (Modified according to Basso et al 
(35)).  
 
1.6 HEMATOLOGIC NEOPLASIA 
The total number of patients who currently suffered from a hematologic neoplasm were 
approximately 30 000 for the year 2012. Lymphoma is the 7th most common malignant 
disease diagnosed in Sweden encompassing approximately 2 600 newly diagnosed cases each 
year. The prognosis and clinical course vary tremendously from indolent forms to highly 
aggressive tumours with rapid manifestation and progression (Cancerfonden’s report 2014).  
Lymphomas can be of B- or T-cell origin and the malignant transformation may occur at any 
stage of differentiation. The vast majority of lymphomas (85%) are of B-cell origin. Here we 
can distinguish B-cells disorders arising from precursor B-cells to mature B-cells. We further 
divide mature B-cell lymphomas in two subgroups of Hodgkin and non-Hodgkin lymphomas 
with a dominance of the latter ones.  
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 Figure 3.  Picture illustrating the origin of mature B-cell lymphomas  
Mature B-cell lymphomas are a heterogeneous group of malignancies regarding histological, 
clinical and morphological features. They may arise in bone marrow but also in other organs, 
mostly lymph nodes and spleen, but also non-lymphatic organs such as skin or central 
nervous system may also be their primary site of origin.  
Following the first discovery of Manolov and Manolova (1972) of +14q as a marker for 
Burkitt lymphoma, Zech et al (1976) defined the marker as t(8;14)(q24;q23) as 
pathognomonic for this disease, and the first characteristic translocation was identified in B-
cell lymphomas (39, 40).  Today, molecular cytogenetic approach using fluorescence in situ 
hybridisation (FISH) and array comparative genome hybridisation (array-CGH) has become a 
daily diagnostic routine. The identification and characterisation of recurrent chromosomal 
aberrancies as hallmarks of lymphoid neoplasm has its reflection in the current WHO 
classification of hematologic malignancies (41).   
The WHO classification divides the lymphoid neoplasms based on their morphologic, 
immunophenotypic, genetic features and clinical presentation. For each neoplasm a cell of 
origin is postulated, reflecting a differentiation stage rather than a real cell in which neoplastic 
transformation actually occurs (41).  
Dark zone 
Somatic hypermutation 
Light zone 
Isotype class switch 
Naive B-cell 
Mantle zone 
Mantle cell 
lymphoma 
Follicular 
lymphoma 
GC#like(
DLBCL(
ABC like 
DLBCL 
Pre-GC Post-GC 
 10 
1.7 B-CELL DEVELOPMENT AND RECEPTOR REARRANGEMENTS.  
Immunoglobulin (Ig) molecules, constitute of Ig heavy chains (IgH) and light chains, of 
either kappa  (Igκ) or lambda (Igλ) type. These proteins are encoded by the IGH locus at the 
14q32, while IGΚ is located at the 2p12 and IGL at the 22q11 position (21). The IGH gene is 
consisted of V, D, J and C segments. IG light genes lack D segments (21).  
B-cell development begins with a rearrangement of IGH and IGK/L in B-cell progenitors in 
the bone marrow. V(D)J in IGH and VJ in IGK/L recombination form a functional Ig (21).  
Notably, the IGH, IGK and IGH loci are commonly affected by chromosomal translocations 
often resulting in activation of oncogenes. This mechanism is observed in many mature B-
cell lymphomas. The frequency of translocations varies a lot depending on the lymphoma 
subtype (21).  
For some lymphomas, the specific IG translocation is considered as pathognomonic for the 
disease and is detected in more than 95% of cases e.g. Burkitt lymphoma is associated with 
t(8;14) (q24;q32) involving the MYC oncogene and mantle cell lymphoma is associated with 
t(11;14) (q13,q32) involving the Cyclin D1 gene (CCDN1) (21).  
In other lymphomas such as DLBCL, IG translocations are detected roughly in half of the 
cases (42). Translocations in DLBCL may be multiple and involve both IGH  as well as a 
light chain locus, the most common is t(14;18)(q32;q21), a hallmark of FL seen in tDLBCL 
(23, 43)  
As IG loci are subject to multiple physiological breaks as a part of the recombination during 
B-cell development, chromosomal translocations involving these regions are believed to be a 
result of mistakes in the recombination processes. IG translocations may lead to constant 
activation of oncogenes most typically through deregulation mediated by enhancers within IG 
loci. Rarely, the fusion transcripts of the IG and oncogenes are observed (21).    
Interestingly, enhancers may keep their activity over distances of several hundred kilobases. 
Such a situation is observed in the case of MYC translocations, where breakpoints affecting 
the MYC gene can be located up to 1 Mb centromeric of MYC in t(8;14) and telomeric of 
MYC in t(8;22) and t(2;8) (21) .  
The most commonly observed rearrangement on non-IG locus in mature B-cell lymphoma is 
rearrangement affecting the BCL6 locus at 3q27. The translocation results in promotor 
substitution and causes deregulation of the BCL6 gene (44-47).  
Other oncogenes known to be targets of IG translocations are known to be juxtaposed 
sometimes directly next to each other through a translocation, e.g. MYC and PAX5 through 
t(8;9)(q24;p13) and BCL6 and MYC through t(3;8)(q27;q24) in t(14;18) positive FL (48, 49).  
Moreover, one of the most common alterations detected in all types of mature B-cells 
lymphoma, is a deletion of the long arm of chromosome 6. The incidence varies from 5% in 
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B-CLL up to 30% in DLBCL (21). The deletions are mostly terminal and the band 6q21 is 
one of the most commonly affected. The second most frequently affected is region 6q25-27 
and the third most common 6q23.  Previous studies have shown inactivation of the 
PRDM1/BLIMP1 gene located in 6q21 in ABC-DLBCL (50, 51). Then, a commonly deleted 
region 6q23.3 encompasses TNFAIP3 (A20) and PERP genes, has been detected in FL and 
marginal zone lymphoma (MZL). Moreover, mutations in A20 have been described in 
classical Hodgkin lymphoma as well as primary mediastinal B-cell lymphoma (52). 
The general rule is that the prognosis is inversely related to the karyotypic complexity (21). 
The most common cytogenetic aberrations in FL and aggressive B-cells lymphomas are listed 
in Table 1. 
Table 1. Overview of frequent and clinically relevant chromosomal aberrations in the most 
common mature B-cells lymphomas (21). (Modified from Mitelman et al 2015 (21)).  
 
1.8  GERMINAL CENTER DERIVED LYMPHOMA (FL, DLBCL) 
 
1.8.1 FOLLICULAR LYMPHOMA 
Follicular lymphoma (FL) is the second most frequent subtype of nodal lymphoid 
malignancies in Western Europe. FL is the prototype of indolent lymphoma, characterised by 
typically slow progression. Nevertheless a number of patients develop increasingly resistant 
disease over time with 3% per year risk of transformation to an aggressive lymphoma, 
associated with poor outcome (53).  
Neoplasm Cytogenetic aberration Frequency (%) 
FL t(14;18)(q32;q21) and variants 
involving BCL2 
80-90% 
translocations involving 3q27/BCL6 <10% FL g1-2,55% FL g3b 
+X, +7, +12/12q, +18/18q, +der 
(18)t(14,18), del6q, del10q, del17p, 
dup1q, der(1p) 
>10% 
DLBCL translocations involving 3q27/BCL6 20-40% 
t(14;18)(q32;q21) 20-30% (GC) 
t(8;14) (q24;32)/t(8q24) 5-15% (GC>ABC) 
+3/3q, +18/18q, +19q, del6q, del9p 10-40% (ABC) 
+1q, +2p13-16, +7,+11q,+12/12q 10-40% (GC) 
+9/9p23-24 50-90% (PMBCL) 
+2p13-16 50-90% (PMBCL, GC) 
B-cell lymphoma 
UNS with features 
intermediate 
between DLBCL 
and B; Burkitt 
lymphoma 
translocations involving 8q24/MYC 40-60% 
t(14;18)/IGH-BCL2 35-50% 
t translocations involving 3q27/BCL6  
t(8,14)(q24,q32) and variants 100% (Burkitt lymphoma) 
dup 1q 30-50% 
+7, +12 10-30% 
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1.8.1.1 Pathology of FL  
FL is a neoplasm composed of germinal center B-cells, typically both centrocytes and 
centroblast/large transformed cells, which usually has at least partially follicular growth 
pattern (41). 
The proportion of centroblasts and centrocytes underlies the grading system: grade 1 
comprising low number of centroblasts (<5 per high power field (HPF)), grade 2 5-15 
centroblasts/HPF, grade 3a >15 centroblasts/HPF , whereas in grade 3b FL is composed of 
solid sheets of centroblasts. Grade 3b FL resemble de novo DLBCL and harbor a different 
molecular profile compared to grade 1-3a FL (41).  
Diagnosis of FL should be based on a surgical excision or lymph node biopsy. Considering 
the heterogeneity of FL, core biopses should be only applied to patients without accessible 
lymph nodes (e.g. retroperitoneal tumours) (Figure 6). FL grading is difficult to assess on 
core biopsies and may not be representative for the whole tumour (54).  
1.8.1.2 Cell of origin 
In follicular lymphoma, tumour cells are organized in follicles and express germinal center 
markers such as Bcl6 and CD10.  Lymphoma cells show also gene expression profiles typical  
for centrocytes and centroblasts, which suggests that FL cells undergo differentiation 
characteristic for GC cells (53, 55). The first hit in a cascade leading to FL is believed to be 
t(14;18) based on the frequency of this alteration and its function in pathogenesis (53).  
It has been suggested that since VDJ recombination occurs in early B-cell development in 
bone marrow, the 14;18- translocation as the first genetic hit may therefore occur in the bone 
marrow (53). Naive B-cells carrying the t(14;18) exit the bone marrow and colonise a 
secondary follicle where they undergo the germinal center reaction (53). Constitutive 
expression of the anti-apoptotic protein Bcl2, which is normally absent in normal GC, gives 
lymphoma cells a survival advantage. (56). Moreover, Bcl2 helps the neoplastic B-cells to 
escape apoptosis, which would normally occur due to weak B-cell receptor affinity (53, 56).  
The origin of FL is a matter of debate. The hypothesis which is recognising naive t(14;18) 
positive B-cells as potential FL progenitor cells is complicated by the fact that very rare 
t(14;18) positive B-cells (at frequency 10-5 – 10-7) are detected in about 50-70% of healthy 
population without any risk of developing lymphoma (53, 57-59). However, we have to 
consider that most of these t(14;18) positive circulating B-cells in healthy individuals are not 
truly ”naive” as studies show. Instead they are germinal center educated IgD+ CD27+ (or 
IgM+CD27+) memory B-cells (56, 60, 61). It has also been shown that FL can arise in both 
the donor and recipient after allogenic stem cell transplantation showing matching complex 
genetic profile (62).  This report also indicated that progenitor lymphoma cell may have far 
more complex genetic alterations than previously suspected (53). 
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FL may be proceeded by an in situ phase - FLIS, which may progress to a clinical disease in a 
subset of patients (63). However, it may be difficult to distinguish this entity from very early 
stage of incidentally detected FL and a lymph node with partial FL involvement (53). 
1.8.1.3 Genetic  landscape of FL 
Around 80-90% of FL show t(14;18)(q32;q21) or very rare variants t(2;18)(p12;q21) and 
t(18;22)(q21;q11) (21).  
In molecular terms t(14;18)(q32;q21) in FL juxtaposes the BCL2 oncogene next to IGH locus 
(64). The breakpoints in the IGH locus affect he region containing the J-segments. This 
translocation originating from failed VDJ rearrangement, is an argument for the theory saying 
that a lymphoma progenitor cell originate in bone marrow rather than germinal center    
The t(2,18)(p12;21) and t(18;22)(q21,11) that juxtapose the BCL2 gene next to IGK and IGL 
loci are rare variants (21).  
Only in about 10% of t(14;18) positive cases, the translocation is the single cytogenetic 
change (65). Otherwise, the recurrent secondary alterations comprise +X, +1q21-44, +7, 
+12q, +18q, del(1)(p36), del(6q), del(10)(q22-24) and development of ploidy (21, 65). The 
most frequent secondary event arising after t(14;18) is a duplication of  the der(18)t(14;18).  
In t(14;18)-negative FL, the most common changes concern chromosome 3 (66). Trisomy 3 
seems to be more frequent among t(14;18) negative than positive FL and the occurance of 
t(3q27) has been reported significantly higher (up to 55%) in FL3b (21, 66). The target gene 
in this region (3q27) is BCL6 (known even as BCL5 or LAZ3), which encodes a 
transcriptional factor important for germinal center formation (29, 45).  
Another common alteration in FL is non-random loss of 1p36. This region encompasses the 
TNFRSF14 gene, which has been shown to be recurrently mutated resulting in a truncated 
protein and decreased surface expression of the receptor (67, 68). Inhibitory or stimulatory 
signals to T-cells can be transmitted to the receptor depending on ligand interactions. 
Mutations in this receptor are recurrent event in FL and act as a link between tumour cells 
and microenvironment (53).  
A variety of cytogenetic and molecular studies have linked loss of 6q as being with 
unfavorable outcome (67). These studies revealed that TNFAIP/A20 (6q23.3), a negative 
regulator of NF-κB signaling and receptor tyrosine kinase EPHA7 (6q16.1), have a tumour 
suppressing role in FL (69).  
Recent studies have shown that germinal center derived lymphomas show a high frequency 
of mutations in histone modifying genes (53).  FL in particular, is characterised by recurrent 
mutations in the histone methyltransferases MLL (89%), previously mentioned EPHA7 
(deletion + methylation 70%), histone acetylases CREBBP (33%), EP300 (8,7%) and MEF2B 
(15,3%), suggesting that it is a disease of the epigenome as well as the genome  (19, 53, 70-
74). 
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One of the best studied histone modyfing genes in lymphoma is EZH2 gene coding enzyme 
that is a catalytic unit of polycomb repressive complex 2 and acts as H3K27 
methyltransferase that catalyses histone H3 Lys 27 methylation (H3K27me3). It has a 
function as transcriptional repressor and also contributes to embryonic stem cell properties. 
EZH2 is essential for normal germinal center formation. Knocking down EZH2 gene leads to 
a total loss of germinal centers (75). Conversely, upregulation of EZH2 induces extent 
follicular hyperplasia. With help of immunohistochemistry, one may appreciate EZH2 
nuclear stain in centroblasts (75). Also, key EZH2 targets (CDKN1A/p21) were shown to be 
differentially repressed and H3K27 trimethylated in centroblasts vs naive B-cells (76). EZH2 
controls proliferation through CDKN1A and blocks GC exit and differentiation program (76).  
EZH2 gene is a common subject of mutations in lymphoma. Mutations in Tyr 641 in EZH2 
have been identified in 7% of FLs and 22% of GC-like DLBCLs leading to increase histone 
H3 Lys27 methylation (H3K27me3) (19).  It is a gain of function mutation and one of the 
most common mutations seen in DLBCLs.  
While in the normal germinal center the expression of wild type EZH2 is similar to BCL6 
showing a decreasing gradient associated with B-cell differentiation towards plasmacells, the 
EZH2 mutant is upregulated in B-cells during germinal center reaction suggesting that 
activating EZH2 mutations lock the B-cells in GC program favoring their proliferation (77) 
Somatic mutation of EZH2 cooperates with co-occurring genetic lesions to accelerate 
lymphomagenesis and disease progression (19, 70, 75). 
EZH2 inhibition as a therapeutic strategy has been shown successful in killing lymphoma 
cells carrying EZH2 activating mutations. Interestingly, it has been shown that EZH2 
inhibitors kill DLBCLs of GC type regardless of mutation whereas non-GC DLBCLs are 
resistant to this treatment (78).  
1.8.1.4 Clinical correlations and disease progression in FL. 
It is possible to distinguish at least two very distinct cytogenetical groups of FL.  
The first group encompassing FL grade 1 and 2 with t(14;18) can progress to FL grade 3a 
which is often associated with acquisition of tertiary cytogenetic aberrations of e.g. 17p 
(TP53), 9p21(CDKN2A) or 8q24 (MYC). This process is associated with unfavorable 
prognosis (21).  
The second group involves mostly FL grade 3b and lack the t(14;18). It often shows a 
translocation involving 3q27 (BCL6) and can progress to DLBCL (21).   
Gene expression profiling studies show distinct differences between FL grade 1,2 and 3a as a 
group compared to grade 3b, indicating a different biological background. Grade 3b FL show 
larger similarities to DLBCL and is in a clinical aspect regarded as such.  
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1.8.1.5 Genetic landscapes and implications for therapy.  
High-throughput sequencing has revealed the genetic landscapes of many malignancies, 
leading to growing interest in ”personalised medicine” (63).  
Mutations that arise during early ”genetic evolution” are common in cancer cells and are 
attractive targets for therapy (63). However, mutations arising during disease evolution are 
rather restricted to a subclone and thus less suited to targeted therapy. Thus the interest in 
contribution of  ”common progenitor cells” (CPCs) in disease relapse and development of 
therapy resistance increases. Understanding the clonal evolution and ability to trace back the 
initiating events of tumourigenesis had become an important issue in cancer biology (63).  
1.8.1.6 Tumour microenvironment. 
The role of the microenvironment for tumour development and its evolution cannot be 
underestimated, however this is when the question like  ”which came first, the chicken or the 
egg” appears. It sill remains unclear if tumour cells drive the changes in the 
microenvironment, allowing the lymphoma cells to establish the clone, or if the changes in 
the microenvironment proceed the ones in tumour cells? The current opinions are suggesting 
that genetic alterations in tumour cells are driving the genetic changes in the tumour 
microenvironment. Another type of correlation seen in the case of lymphoma is that a more 
aggressive genetic/epigenetic pattern is associated with more aggressive changes in the 
microenvironment.  
Microenvironment in germinal center derived lymphomas, and FL in particular, involves 
interactions of lymphoma B-cells with T-cells and macrophages as well as follicular dendritic 
cells.  
The microenvironment can support tumour growth and survival, and suppress the anti-
tumoural immune response. FL cells express high levels of cytokines (CXCR4 and CXCR5) 
and are attracted to follicles by cytokines such as CXCL13 released by follicular T-helper 
(FTh) and follicular dendritic cells (FDC) (53, 79).  As antigen presenting cells the FDCs 
contribute to BCR signaling. FTh cells secrete cytokines like IL-4, which binds to its receptor 
on lymphoma cells triggering the ERK and STAT6 signaling.  It has been demonstrated that 
increased number of tumour associated macrophages is associated with poor prognosis (53, 
79). Increased microvessel density and angiogenic activity have also been associated with 
poor outcome in FL. Another important mechanism concerns the adaptive immune response. 
Malignant B-cells induce T-cell exhaustion through constant IL-12 secretion and 
programmed cell death-1 receptor (PD-1 receptor) stimulation, which results in impaired T-
cells function and decreased T-cell motility (80).  B-cells affect the function of many T-cells 
subsets through inducing the conversion of regulatory T-cells (T-regs) that in result suppress 
the activity of other effector T-cells (of both CD4+ and CD8+ subsets) (80).  
Tumour microenvironment is an important and promising target for therapies. Drugs like 
Lenalidomide targeting angiogenic activity and largely understood microenvironment have 
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been shown to present good response to a treatment of lymphomas in combination with 
standard chemotherapy. Promising results are also seen in anti-PD1L drugs that are able to 
reduce PD1L expression on tumour cells and reverse the exhaustion of T-cells regaining their 
normal function and motility (81).  
 
1.8.2 DIFFUSE LARGE B CELL LYMPHOMA 
Diffuse large B-cell lymphoma (DLBCL) is the most common B-cells lymphoma that 
comprises around 500 newly diagnosed cases in Sweden every year. DLBCL is a diagnosis 
that encompasses a group of lymphomas that fulfill a WHO definition but are extremely 
heterogeneous and differ in morphology, immunophenotype and molecular as well as clinical 
characteristic and behaviour. Patients who suffer from DLBCL respond differently to 
treatment, some are cured and achieve complete remission (CR) but some succumb to the 
disease.  
DLBCL is according to the WHO definition 2008 : “ a neoplasm of large lymphoid cells with 
nuclear size equal to or exceeding normal macrophage nuclei or more than twice a size of  a 
normal lymphocyte and that has a diffuse growth pattern” (41).  Biological and clinical 
studies have subdivided DLBCL into morphological variants with immunohistochemical 
subgroups representing distinct disease entities. However, the large number of cases remains 
biologically heterogeneous, unable to be classified according to clear and accepted criteria of 
division. These tumours are classified as DLBCL not otherwise specified (NOS) and this 
group comprises the vast majority (90%) of all diagnosed DLBCLs (including the tumours 
studied in this Thesis). The remaining 10% of the DLBCLs are associated with specific 
characteristics as listed in the Table 2.   
In spite of its heterogeneity, most of the patients continue to be treated in a uniform fashion, 
where R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), is the 
most commonly used regimen. 
 
Why to perform molecular diagnosis of DLBCLs? 
Molecular studies are done in order to delineate ”grey zone” lymphomas, identify prognostic 
subgroups, but most important of all, to identify molecular subtypes and pathways that could 
be relevant for targeted therapy.   
Gene expression profiling (GEP) studies have identified in DLBCL NOS,  at least 2 distinct 
molecular subtypes, referred to as germinal center B cell (GCB or GC) and activated B cell 
(ABC). However, even with this approach, about 15% of patients remain unclassifiable. The 
GC and ABC groups represent lymphomas arising from different stages of B-cell 
differentiation. This molecular approach has shown to have prognostic implications where the 
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ABC subtype is characterised by poor prognosis and inferior outcome following R-CHOP 
therapy (3 year progression free survival of 40% as compared to 75%, p<0,001) (55) (82). 
What is also important from a clinical point of view, is the fact that the molecular subtyping 
shows that the lymphomas are driven by very different oncogenic signalling pathways, which 
could be differentially exploited for therapeutic benefit.  
Table 2. The short summary of classification of DLBCL NOS, DLBCL subtypes, and other 
B-cell lymphomas according to WHO 2008 (41). (Modified according to Klapper 2015).  
1.8.2.1 GC DLBCL 
GC DLBCLs are considered to originate from lymphoid cells residing in the germinal center  
and expressing CD10, BCL6 and LMO2 (LIM domain only-2) (82).  
About 30-40% of GC DLBCLs possess a t(14;18), 30% have C-REL amplifications, 20% 
carry mutations of EZH2 and 10% have a deletion of PTEN. All of the above mentioned 
alterations are characteristic for DLBCLs of GC type and are practically never seen in ABC 
DLBCL (Figure 4) (82). EZH2 is known to be “a master regulator” of germinal center 
differentiation. However, it is also involved with BCL6 in B-cell lymphoma development.  
(77). As described before, somatic point mutations within exon 15 of the EZH2 gene result in 
a replacement of a single tyrosine (Tyr 461) within the EZH2 protein. This change leads to a 
WHO classification of DLBCL 
I. Diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) 
II. Diffuse large B-cell lymphoma subtypes:  
• Primary DLBCL of the CNS,  
• Primary cutaneous DLBCL, leg type 
• EBV positive DLBCL, of the elderly 
• DLBCL associated with chronic inflammation 
III: Other B-cell lymphomas of large cells: 
• Mediastinal large B-cell lymphoma 
• Intravascular large cell lymphoma 
• Lymphomatoid granulomatosis 
• ALK positive LBCL 
• Plasmablastic lymphoma 
• LCBL arising in HHV8-positive multicentric Castleman disease 
• Primary effusion lymphoma 
• T-cell/histiocyte rich large B-cell lymphoma 
IV: “Grey zone” lymphomas: 
• B-cell lymphoma unclassifiable with features intermediate between DLBCL and Burkitt 
• B-cell lymphoma unclassifiable with features between DLBCL and classical Hodgkin 
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gain of function and an increased methylation of histone 3, which promotes 
lymphomagenesis by transcriptionally silencing key regulator genes (82). Therefore, both 
BCL6 and EZH2 have the potential to become important targets for therapeutic agents. 
The other main pathway activated in GC DLBCL and other types of lymphoma is 
phosphatidylinositol 3 kinase (PI3K)/AKT/MTOR signaling pathway which is crucial for cell 
growth and metabolism (82). A deletion of the PTEN tumour suppressor gene has been 
detected in 10% of these lymphomas, and the loss of PTEN protein expression detected by 
IHC has been seen in 50% of GC DLBCLs  compared to 14% among non-GC cases, 
indicating other mechanisms involved in loss of PTEN function. The constitutive activation 
of PI3K/AKT/MTOR pathway in GC DLBCL may be a possible target for  inhibitory therapy 
(82).   
The anti-apoptotic protein Bcl2, is commonly overexpressed in both GC and non-GC 
DLBCL, although the mechanisms are different. In GC type of DLBCL, overexpression is 
mainly due to presence of t(14;18). However, in non-GC DLBCLs it is due to transcriptional 
upregulation or gene amplification (82, 83). The use of Bcl2 inhibitors is a promising option 
for treatment of DLBCLs, especially of GC type (53). 
Just as a clarification, the term ABC subtype refers to GEP profiling, while the term non-GC 
is used in the aspect of immunohistochemistry (IHC). Both terms are therefore differentially 
used in the text depending on context. Even though these groups overlap to an extent a direct 
translation is not complete. This aspect is further discussed below. 
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Figure 4.  Key oncogenic pathways in DLBCL (GC and ABC type), Abbr: cb, centroblast; 
cc, centrocyte; pb, plasmablast; pc, plasma cell. (Modified from Sehn and Gascoyne, Blood 
2015 (82)). 
 
1.8.2.2 ABC DLBCL and non-GC DLBCL 
ABC DLBCLs originate from B cells at the plasmablastic differentiation stage, prior to 
germinal center exit. The ABC type of DLBCL relies on NF-κB pathway constitutive 
activation, which is a pathogenetic hallmark of this ABC subtype and promotes cell survival, 
proliferation and inhibition of apoptosis (82). It occurs to a large extent due to constitutive 
activation of the CBM signaling complex (composed of CARD11, Bcl10 and MALT1), 
which is normally active in response to antigen stimulation (Figure 5). In ABC DLBCL the 
genetic aberrations may activate CBM complex with 10% of cases show activating mutations 
of CARD11 or chronic activation of B cell receptor (BCR) signaling. B cell receptor harbors 
mutations in CD79a or CD79b in about 20% of cases (38, 82). Mutations in MYD88 are 
detected in >30% of ABC DLBCL, resulting in NF-κB upregulation. Also loss of function of 
TNFAIP3 (A20) occurs often via mutation and deletion, resulting in activation of NF-κB 
signaling.  The drugs targeting NF-κB pathway and its oncogenic drivers are promising 
therapeutic agents (82).  
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Figure 5. Chronic B-cell receptor activation and MYD88 mutations in ABC DLBCL. 
Multiple mutated BCR signalling pathway agents have been identified in BCR (CD79b) or 
downstream the pathway CARD11 leading to chronic NF-κB activation. A star marks 
mutations occuring in various adaptors in the BCR signaling pathway. (Modified from 
Bachy, Seminars in Hematology 2015 (38)).  
 
1.8.2.3 Determining the cell of origin  
The cell of origin has a prognostic and predictive meaning, which makes it a potential  
therapeutic targets, there is a great need for reliable method in assessing cell of origin and 
subtype of DLBCL (82). Gene expression profiling (GEP) is not routinely available and 
hence there is a need for a more practical well-functioning IHC based algorithm. The Hans et 
al algorithm is commonly used for distinguishing GC and non-GC patients based on the 
presence of 3 IHC markers (CD10, Bcl6 and MUM-1) (84). Different algorithms have been 
proposed since then (Choi, Muris, Nyman, Natkunam, Tally and Visco-Young) (85). All of 
them were very promising at the beginning but turned out having various levels of 
concordance with GEP analysis. However, the Hans algorithm remained the most commonly 
established in the clinical routine for a decade. Having a practical approach to algorithms 
used in clinical diagnostics, one may make an observation that CD10 is a reliable marker of 
germinal differentiation, distinguishing GC subtype with >95% concordance with GEP 
analysis. A problem appears as far as other surrogate biomarkers are concerned, giving 
overall agreement rating from 80-93% depending on a study. In conclusion – we are able to 
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diagnose a GC DLBCL with very good confidence (>95%), if it shows expression of CD10 
but otherwise IHC based subclassification still is a challenge, where we have even about 20% 
misclassification (Klapper W. at EHA meeting 2015). In search for practical application of  
GEP studies in diagnostic routine, the 20 gene assay using NanoString technology in paraffin 
embedded tissue (Lymph2Cx) is a method currently undergoing validation (82).  
1.8.2.4 Role of MYC and BCL2 expression in DLBCL, “double hit lymphomas” 
The MYC  oncogene rearrangment is as hallmark of Burkitt lymphoma, but can also be 
identified in about 10% of DLBCL patients (82). MYC overexpression promotes cell growth 
and proliferation, and many studies have shown poorer outcome in patients with MYC 
expression. A number of studies have also revealed the impact of MYC under influence of 
BCL2. The aggressive character of these tumours stresses the role of early diagnosis of 
”double hit” lymphomas in diagnostic and clinical practice. Concurrent MYC and BCL2 
translocations are identified in 5% of DLBCLs and represent a treatment resistant subgroup 
(82). The median survival in this group is about 8 months (82, 86, 87). However, more 
studies are needed to identify the impact of the corresponding part involved in MYC 
rearrangement, as not all of the patients with “double hit” lymphomas may have such a poor 
outcome (82). Importantly, the overexpression of the MYC protein is more commonly due to 
an upregulation by additional mechanisms such as amplification and can be demonstrated by 
IHC in 25-30% of DLBCLs (82). Negative prognostic impact of high MYC protein 
expression is observed first of all in patients with coexpression of the Bcl2 protein. Patients 
with coexpression of MYC and Bcl2 proteins are commonly referred as ”dual expressers”. 
This group comprises about 25% of DLBCL patients (82). Double expression of MYC and 
Bcl2 is associated with significantly poorer outcome of these patients as compared to those 
with expression of one or neither protein (5 year progression free survival (PFS) is about 25% 
following R-CHOP) (82, 87, 88).  Notably, the “dual expressers” belong more often to the 
non-GC type of DLBCLs, which  may also be related to an inferior survival of these patients 
(82). According to these findings, MYC and Bcl2 expression should be routinely assessed at 
diagnosis (both the presence of translocations and protein overexpression) to identify a poor 
risk subgroup and to choose between various treatment options.  The overview of studies 
showing the assessment of prognostic effect of MYC and Bcl2 is illustrated in Table 3.  
Study Therapy Result 
Johnson et al. (JCO 2012) R-CHOP Negative prognostic effect if Bcl2 is 
coexpressed 
Green et al. (JCO 2012) R-CHOP Only analysed in combination with Bcl2 
Hu et al. (Blood 2013) R-CHOP Negative prognostic effect if Bcl2 is 
coexpressed 
Valera et al. (Hematologica 
2013) 
R-CHOP and 
similar 
Poorest if Bcl2 is co-expressed 
Horn et al. (Blood 2013) CHOP and R-
CHOP 
Poorest if Bcl2 is co-expressed 
Table 3. Clinical relevance of MYC and Bcl2-expression in DLBCL (according to Klapper 
EHA 2015). 
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Although the MYC and Bcl2 “dual expressers” are well studied, MYC and Bcl6 “dual 
expressers” are less well characterized and more studies concerning the impact of the 
coexisting effect of these proteins are needed. Moreover, “triple expressers” involving MYC, 
Bcl2 and Bcl6, although rare, do occur.  
 
1.8.3 TREATMENT 
1.8.3.1  Treatment of FL  
First line treatment for the patients with limited disease stage I-II, radiotherapy, has a curative 
potential (54). “Watch and wait” approach can also be considered in asymptomatic patients. 
Another option for these patients is the monoclonal antibody, rituximab (anti-CD20 
monoclonal antibody) in monotherapy if  “watch and wait” is not acceptable. (54). When 
patients become symptomatic the choice of treatment varies from single to combination 
therapy. The addition of rituximab to several chemotherapy regimens was shown to improve 
progression free survival (PFS) and overall survival (OS). The CVP regime 
(cyclophosphamide, vincristine and prednisone) was for years one of the standard treatments 
followed by versions including rituximab (R-CVP) that is now used in many countries. R-
CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) is a very 
active therapy, but some studies shown that R-bendamustine is as effective in patients with 
FL grade 1-2, although for patients with FL grade 3, R-CHOP is preferable (54).  
1.8.3.2 Standard therapies in newly diagnosed DLBCL 
DLBCL is usually treated with rituximab in combination with the chemotherapy regime R-
CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and about 60-
70% of patients are cured. Those, that relapse and are refractory to treatment receive salvage 
therapy and high dose therapy followed by autologous stem cell transplantation.  
Other regimens used in treatment of newly diagnosed DLBCL include R-ACVBP consisting 
of rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone with 
subsequent consolidation with high dose methotrexate and holoxan plus ifosfamide and 
cytarabine (38, 89).  
Another dose dense regimen showing efficacy in DLBCL treatment is DA-EPOCH based on 
continuous infusion of dose adjusted etoposide, prednisone, vincristine, cyclophosphamide, 
and doxorubicine with rituximab (38, 90, 91).  
Although the R-CHOP remains the main core for the therapeutic approaches with the benefit 
of most of the DLBCL patients, there is still a group of patients that relapse underlining the 
need for optimization of front line therapy and development of new more effective salvage 
strategies (82). 
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1.8.3.3 Novel therapies in DLBCL 
 Novel therapies have been introduced during the past few years taking into consideration 
molecular subtypes of DLBCL, and thus targeting the specific pathways involved in the 
pathogenesis of this heterogeneous group of diseases. Examples of some prototypic drugs 
associated with a specific molecular pathway are listed in table 4.  Multiple therapies 
targeting NF-κB pathway or the B-cell receptor signaling are under the evaluation process. 
These drugs would be most suitable in ABC DLBCL as these pathways are constantly active 
in this subtype (82).  Bortezomib, a proteasome inhibitor blocking degradation of IκB 
(inactivating protein for NF-κB) has been shown to bring benefit in treatment of ABC 
DLBCL in combination with DA-EPOCH in patients with relapsed DLBCL (82, 92). Current 
trials are investigating the combination of bortezomib with R-CHOP in untreated patients 
(82). Therapies targeting B-cell receptor pathway (BTK, SYK, PI3K) are under investigation 
and bring a promise of targeting multiple components at once (82). Ibrutinib (Bruton’s 
tyrosine kinase inhibitor) has been shown to induce response in 41% of ABC DLBCL 
patients as compared to 5% GC DLBCL patients (82, 93). The SYK inhibitor fostamatinib 
disodium has demonstrated the response in more than 20% of patients with refractory 
DLBCL (94, 95). Notably, Idelalisib (PI3K-δ) has shown promise in indolent NHL but has 
not been fully investigated in DLBCL (96, 97). Based on the frequent activation of 
PI3K/ACT/MTOR pathway in GC DLBCL, this drug could be used in the treatment of this 
subgroup of lymphomas. (82). Another type of drugs showing promising results in 
combination with R-CHOP therapy is lenalidomide, which is an immunomodulatory drug 
with antiangiogenic activity and inhibitory effect on NF-κB pathway (98). In a retrospective 
study of patients with relapsed DLBCL lenalidomide appeared to have better effect on ABC-
DLBCL as compared to GC type with 52% vs 9% response rate (99). Lenalidomide has been 
successfully combined with R-CHOP giving promising results in terms of overcoming the 
negative prognostic impact of ABC-DLBCL phenotype (100, 101). The combination of 
rituximab with CHOP has improved the outcome in DLBCL dramatically and therefore 
further attempts of improving the targeting of CD20 are investigated. Obinutuzumab and 
ofatumobab as compared to rituximab are under evaluation. Additional monoclonal 
antibodies targeting various B-cells surface markers (for ex. CD79b) are currently 
investigated (102). Taking into consideration the favorable outcome with R-CHOP treatment, 
novel therapies are likely to represent the additives to this backbone (82). The identification 
of prognostic markers and development of molecular assays providing the information on the 
most suitable treatment for individual patient would be a suitable attempt for future routine 
clinical use.  
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Agent Target Molecular subgroup 
Bortezomib NF-κB ABC 
Fostamatinib SYK ABC 
Ibrutinib BTK ABC 
Enzastaurin PKCβ ABC 
Idelalisib PI3K GC? ABC? 
ABT-199 BCL2 GC, “dual expressers” 
EZH2 inhibitors EZH2 GC 
BCL6 inhibitors BCL6 GC 
Lenalidomide NF-κB, 
microenvironment 
ABC 
Obinutuzumab CD20 all 
Ofatumobab CD20 all 
Polatuzumab vedotin CD79b all 
Table 4. Selected novel targeted agents under evaluation in DLBCL with target and patient 
subgroup that may more likely benefit from this therapy (adapted from Sehn et al. Blood 
2015 (82)). 
 
1.8.4 TRANSFORMATION OF FOLLICULAR LYMPHOMA TO DIFFUSE 
LARGE B CELL LYMPHOMA. 
1.8.4.1 Clinical aspects  
Histologic transformation (HT) defines the transformation from indolent lymphoma to more 
aggressive form. (103). Transformation is a well known aspect of natural history of the 
indolent lymphomas. It is most commonly occuring in FL with subsequent transformation to 
DLBCL but has also been described for other indolent lymphomas like marginal zone 
lymphoma, lymphoplasmocytic lymphoma, lymphocyte predominant Hodgkin lymphoma 
and in small lymphocytic lymphoma/chronic lymphocytic leukemia (Richter syndrome) 
(103).  
The risk of transformation for FL varies in different studies from 24% to 70% and about 30% 
in 10 years (104). These differences may depend on the patient cohorts, follow-up time and 
diagnostics. An risk for transformation is estimated to occur 2% to 3% per year, as observed 
in several studies (104). This incidence remained the same even in the era of rituximab, 
which is suggests that rituximab itself may not diminish or influence the risk of 
transformation (103).  
The risk of transformation is higher for the patients with high Follicular Lymphoma 
International Prognostic Index (FLIPI). Other adverse clinical factors may be advanced age or 
high lactate dehydrogenase (LDH) level (103).  
The impact of treatment on transformation is a subject of debate (105). It has been suggested 
that a more aggressive treatment of the low malignant lymphoma is associated with lower 
risk of transformation but it was not confirmed by other studies (106). Also, a controversial 
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aspect of introducing early treatment was shown to be associated with lower transformation 
risk in some studies but has not been confirmed by others (103, 107).  
Clinical features of transformation include increased LDH, presence of B-symptoms, 
hypercalcemia, and a localised growth or presence of new extranodal sites of disease.  A 
number of studies have shown clinical utility of positron emission tomography (PET) scan to 
detect transformation, High standardised uptake value (SUV) on a FDG-PET correlates with 
more aggressive histology (103). 
The overall survival (OS) of patients with transformation was about 1-2 years. However, 
several studies suggest the survival may be more favourable during the rituximab era. Link et 
al. shown in 2013 that outcome of the patients who underwent transformation from FL  is 
even similar to those with primary DLBCL when treated with R-CHOP (103, 108) . 
The treatment approach for a patient is usually individualised. There is no standard therapy 
for patients with tDLBCL. Therefore there is a need for randomised studies that can be used 
to guide this practice (103). 
There is also a need to determine biomarkers that can be useful for predicting transformation 
as there are very few useful markers that can be reliably used in clinical practice. In the era of 
targeted therapies where the treatment is based on molecular profile of the disease, 
identification of the subclones potentially responsible for predicted transformation already at 
the diagnosis can guide treatment and have direct clinical implications. 
1.8.4.2 Histopathological and molecular aspects of transformation  
The definition of histological transformation may seem clear but it is complicated by the fact 
that diagnosis is often based on histological analysis made on core biopsy, fine needle 
aspiration or on clinical ground only (103). The diagnostic gold standard says that the 
suspicion of histological transformation should be confirmed, if possible, on excisional 
biopsy or representative core biopsy followd by repeated biopsy at  progression is 
recommended (103). Another problem is the complex clonal architecture of FL which is 
composed of different subclones either mixed or restricted to specific sites, and undergoing 
constant evolutionary changes during progression and transformation or even “multiple 
transformations”, that can be limited to specific sites (Figure 6) (103).   
Heterogenous distribution of subclones at progression and transformation requires that 
selection of the biopsy site is based on clinical features and PET scan, so that site of the 
aggressive subclone is sampled rather than a low-grade subclone (109).  
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Figure 6. Different scenarios of distribution of subclones in FL to tDLBCL a) subclones well 
mixed, b) subclones restricted to specific sites, c) regional progression limited to specific sites 
d) transformation with remnant low grade component confined to specific nodes. Proposed 
clonal evolution above. (Modified and adapted according to Casulo et al 2015 (109)).  
 
Genetic analyses indicate that there is no single mechanism driving transformation from FL 
to DLBCL, and that several mechanisms are affected during this process (109, 110). 
Changes in chromosomal copy number i.e  “chromosomal number variation” (CNV) have 
been suggested to be the key mechanisms driving transformation and permitting mutations to 
take place. Pasqualucci et al found that an increase in genomic instability accompanied 
transformation based on CNV analysis (110).  
Recent efforts to identify genetic alteration associated with transformation have identified 
events occurring early in life history of FL. The most common genetic alterations associated 
with FL, the t(14;18)(q32;q21) translocation, results in overexpression of the antiapoptotic  
protein Bcl2 . Moreover, mutations in the histone modyfing gene MLL2 (as well as other 
histone modifiers such as CREBBP and EZH2 ) occur in > 80% of the early indolent FL cases 
and are present in nearly all the tumour cells, suggesting that they are early driver events. 
During transformation they remain stable and clonally dominant which suggests that they 
may represent key events funding the common progenitor cell of FL (111). Moreover, 
Pasqualucci et al suggested that these mutations may encourage the “mutator” phenotype of 
FL, allowing AID (activation induced cytidine deaminase) to access inappropriate regions of 
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the genome leading to aSHM (aberrant somatic hypermutation) and genetic instability driving 
transformation, suggesting that intraclonal variation due to a SHM may be a predictor of 
transformation (109, 110).  
Known molecular markers with a role as predictors for transformation are few and their 
clinical application is limited. Several recurring DNA copy number alterations in FL have 
been associated with transformation (112).  Among them gains of 2p, 12q13-14, 18q21 and 
Xq as well as loss of 1p36, 6q and 17p have been suggested to be associated with FL 
transformation. 
Transformation into DLBCL involves regulators of tumour suppression, cell cycle control, 
cell proliferation and show changes in TP53, MYC and CDKN2A which is associated to more 
aggressive phenotype (111). 
The most frequent genetic aberration seen in transformation is the loss of CDKN2A/B in 
about 45% of DLBCL transformed from FL. CDKN2A/B encodes two tumour suppressor 
genes whose protein products (p14-ARF, p16-INK4A and p15-INK4B) have important 
function in cell cycle regulation and the stabilising of TP53 and they are mutually exclusive 
(111). MYC oncogenic effect is a result of chromosomal translocations, gains, amplifications 
and mutations, encompassing about 40% of cases.  Deregulated MYC oncogenic activity may 
give advantages to the transformed clone concerning its proliferative ability and metabolism.  
A number of gene expression profiling studies using paired tumours of FL and subsequent 
DLBCL have been published. However, these studies are based on small numbers of paired 
samples (113-115). In 2002, Lossos and colleagues, have studied 12 pairs of matched FL and 
DLBCL tumours (113, 116) and they have described two subgroups; one with increased MYC 
and its targets, that appeared to lose proliferation control; and the other with decrease in MYC 
and downstream targets associated with loss of apoptotic signalling (113, 116). One year 
later, Elenitoba-Johnson and colleagues suggested the p38 MAP kinase as important pathway 
during transformation (114). Davies et al. in 2007 studied 20 paired samples of FL with 
corresponding DLBCL and could show that TP53 mutations, TP53 loss, CDKN2A loss and c-
REL amplification were associated with increased proliferation and transformation (113, 
115). In 2009, Gentles and colleagues have described a “pluripotency signature” related to 
specific embryonic stem cell, in transformed DLBCL but not in FL- counterparts (113, 117). 
Last year, Brodtkorb and colleagues presented an integrated analysis of gene expression and 
copy number changes, which revealed that genes involved in the NF-κB pathway (BTK, 
IGBP1, IRAK1, ROCK1, and TMED7-TICAM2) are significantly associated with FL 
transformation (118).  The most common genetic alterations associted with transformation 
are illustrated in Figure 7.  
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Figure 7. Common genetic alterations underlying histologic transformation of FL to DLBCL. 
(According to Bouska et al 2014 (112)).  
 
The nomenclature of tumours transformed from FL to DLBCL has also been a subject of 
debate. In latest publications of Pasqualucci and colleagues and Okosun et al, the authors 
refer to transformed lymphomas as “transformed follicular lymphoma” (tFL) pointing out 
their origin (110, 119). As a pathologist, however, I share the opinion that these tumours are 
already classified as DLBCL and behave as such, so the term “transformed DLBCL” or 
tDLBCL is more correct and such the term is used in the Thesis.  
The vast majority of DLBCL cases transformed from FL present as GC subtype. However, 
there are subsets of tDLBCL that present as ABC-tDLBCL or unclassifiable, according to 
some studies encompassing about 30% of tDLBCL cases (112). The frequencies of 
underlying copy number alterations and specific mutations differ significantly between these 
two groups (GC and ABC DLBCL) as illustrated in Figure 8. The ABC-tDLBCL type show 
more frequently gains of chromosome 3, 3p and 3q and 1q44, and losses of 1p13.1 and 
1p36.11-p35.3 encompassing CD58 and ARID1A, and loss or double loss of 6q including the 
negative regulator of NF-κB pathway TNFAIP3. However, the non-GC type of tDLBCL 
shows more commonly loss of 19p13.3-p13.2 including CD70. On the other hand gains of 
chromosomes or arms of 7 and 12 were more frequent in GC type of tDLBCL (112). Also the 
mutational pattern differs between the non-GC and GC types of tDLBCL. Mutations more 
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typical for non-GC encompasses genes CD79B, CARD11, MYD88, TNFAIP3, while the GC 
type more often is associated with mutations in genes SOCS1, BCL2, MLL2 (Figure 8).  
 
Figure 8. Molecular subtypes associated with transformation from FL to DLBCL. 
(According to Bouska et al 2014 (112)).  
 
1.8.4.3 The microenvironment in FL transformation 
Gene expression profiling (GEP) have identified pattern corresponding to the role of 
microenvironment in FL progression and transformation. Two general aspects are widely 
discussed: the microenvironment’s role in supporting proliferation and blocking apoptosis 
and its antitumoral immunologic effect (109). 
Also the microenvironment of FL may have impact on predicting transformation risk and 
survival. The loss of B2M expression, also known to be associated with transformation, could 
be associated with immunomodulatory changes of the microenvironment proceeding 
transformation. It has also been suggested that immune changes in microenvironment may 
possibly induce “mutator phenotype” by for example affecting the expression of AID 
(Activation Induced (Cytidine) Deaminase) in FL cells that may result in aberrant somatic 
hypermutations (aSHM) in FL progenitor cells (109). 
Several changes in microenvironment have been described to accompany the transformation. 
The typical changes described in non-neoplastic cells include loss of follicular dendritic cells, 
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increased interfollicular CD4+ T-cells, decreased number of regulatory T-cells and PD1+ T-
cells, increased microvessel density, all of which have been linked to an increased risk of 
transformation (120). However, many of these studies refer to patient cohorts not uniformly 
treated and treated without routine use of rituximab. These observations must be re-evaluated 
in the current era of rituximab treatment, possibly in the context of uniform therapy and 
randomized controlled clinical trials (113). 
1.8.4.4 Clonal evolution  
The clonal evolution of a tumour may occur through either a linear model in which the 
predominant clone expand acquiring novel genetics changes leading to progression of 
through branching model in which the common progenitor cell evolves to the initial tumour 
and then progresses stage by stage through different clone evolution and through distinct 
genetic pathways (111).  
Transformation of follicular lymphoma occurs almost exclusively through branching rather 
than linear model.  The dominant clone arises in most patients from an ancestral mutated 
common progenitor cell evolving through acquisition of genetic events shared partially 
between the indolent and transformed forms (111). This is different from CLL to DLBCL 
transformation occurs mostly through a linear model of evolution where the DLBCL is a final 
stage of progressive expansion of the original founder CLL clone, accumulating genetic 
lesions in an additive way (111).  
1.8.4.5  Treatment challenges and future directions 
The treatment approach for a patient with transformation is very often individualised and 
there have been no randomized studies in a modern time that can be used as guidelines (103). 
There is therefore no standard therapy for patients with transformation and treatment options 
are based on previously received regimens and response to them. The historically poor 
prognosis for these patients resulted in the treatment approach based on high dose therapy 
(HDT) and autologous stem cell transplant (ASCT), the treatment approach shared by many 
centers (103).  
The promising results are seen in treatment with autologous T-cells expressing and anti-
CD19 chimeric antigen receptor (CAR), also in case of patients with DLBCL who has 
progressed after autologous stem cells transplantation (121). Chimeric antigen receptors 
(CARs) are fusion proteins with antigen-recognition domains and T-cell activation domains. 
T-cells expressing anti-CD19 CARs recognize and kill CD19+ target cells. The infusions of 
CAR T-cells can be administrated together with various chemotherapeutic regiments in 
treatment of DLBCL, as showed by Kochenderfer and colleagues (121). A prerequisite for 
effective treatment of lymphoma with T-cells is infiltration of malignant tumour mass by T-
cells. The toxicity is the most troublesome side effect experienced by patients including 
neurologic toxicity and hypotension but it has been shown released completely after a short 
time period (121). Infusion of anti- CD19 CAR T cells remains the potentially powerful new 
treatment for chemotherapy refractory B-cell malignancies. 
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2 AIMS OF THE STUDY   
 
 
The overall aim of this thesis was to identify the genetic events underlying the progression 
and transformation of indolent follicular lymphoma  (FL) to the more aggressive diffuse large 
B-cell lymphoma (DLBCL) and to outline molecular alterations distinguishing DLBCL with 
GC and non-GC phenotype.  
More specifically, the aims were to identify: 
- distinct molecular events marking progression from FL to DLBCL that could 
be developed as prognostic markers for application in clinical practice. 
-  proteome changes characteristic for GC and non-GC DLBCL lymphomas in 
order to identify new diagnostic and prognostic markers as well as potential therapeutic 
targets.  
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3 MATERIALS AND METHODS  
 
3.1 PATIENTS AND TUMOUR SPECIMENS  
3.1.1.1 Paper I   
The tumour samples were obtained from 50 patients diagnosed with various lymphoma 
subtypes between 1996 and 2008. The samples were retrieved from the archives of the 
Department of Pathology-Cytology at Karolinska University Hospital, Solna and the 
diagnostic material was reviewed according to the WHO 2008 classification (41). The tumour 
material encompassed a spectrum of indolent and aggressive lymphomas including B-cell 
chronic lymphatic leukemia (B-CLL) (no=8); immunocytoma (no=2); mucosa associated 
lymphoid tissue lymphoma (MALT lymphoma) (no=6); mantle cell lymphoma (no=6); 
follicular lymphoma (FL) grade 1-3a (no=6); diffuse large B-cell lymphoma (no=9); Burkitt 
lymphoma (no=5);and classical Hodgkin lymphoma (no=8). Anonymised biopsies from 
reactive tonsills and lymph nodes were used as controls. The FL cases were included in a 
study performed previously by one of the co-authors (122). 
3.1.1.2 Papers II, III and IV 
In Paper II, we studied 81 tumours comprised of 21 FL, 31 transformed DLBCL (tDLBCL) - 
all of them showing germinal center (GC) related immunophenotype - and 29 de novo 
DLBCL (dnDLBCL: 10 showing GC and 19 of non-GC phenotype), collected from a total 60 
patients diagnosed between 1985 and 2007. Paired tumour samples were available from 15 
patients, of which 3 patients contributed with more than 2 consecutive samples.  Fresh frozen 
tumour tissues were identified from medical files of the Departments of Pathology-Cytology 
at Karolinska University Hospital, Solna and Uppsala Academic Hospital, Sweden. The 
diagnostic material was reevaluated according to the WHO 2008 classification (41).  All the 
tumours from Karolinska University Hospital (1-47) were presented for the first time, 
whereas the tumours from Uppsala Academic Hospital (48-81) were previously reported in a 
series of cases investigated by conventional CGH (123).  
In Paper III, 12 samples were obtained from 4 patients with an indolent FL and a tDLBCL 
counterpart, first diagnosed with FL between 1982 and 1997. Three patients (P1, P2 and P3) 
contributed with paired FL-tDLBCL tumours, whereas in case of one patient (P4) – a total of 
6 consecutive tumours could be evaluated (4 FL and 2 tDLBCL). The detailed clinical 
charateristics of the patients is described in supplementary data of the Paper III. The material 
from all the patients (P1-P4) was obtained from Department of Pathology at Uppsala 
Academic Hospital and previously studied by conventional CGH (123) and array CGH (124).  
In Paper IV, a cohort of 31 patients diagnosed as DLBCL (15 GC and 16 non-GC; 11 
tDLBCL and 20 dnDLBCL) at the Department of Pathology, Karolinska University Hospital, 
Solna between 1999 – 2007 was studied. For two of the patients with tDLBLC, the FL 
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component was also available. TMA was constructed from 30 DLBCL, 2FL and 2 normal 
lymph node controls. IHC on one of the dnDLBCL was performed separately, since this 
tumour was not available for TMA. The patient characteristics are available in Table 1 in 
Paper IV. The patient cohort consisted of 19 men and 12 women with a median age about 60. 
The vast majority of the patients received R-CHOP therapy and 16 of 31 patients were in 
complete remission (CR) at the latest follow-up in 2014.  
The patients’ material studied in Paper IV is also a part of the tumour material investigated 
and reported in Paper II . 
 
3.2 METHODS  
 
3.2.1 DNA preparation 
In this thesis DNA was prepared from fresh frozen tissue and used for array-CGH and WES 
studies. The same quality DNA was also used for copy number PCR analysis with the 
exception of one case where the fresh frozen material was not available and instead DNA 
material from formalin fixed paraffin embedded tumour tissue was obtained. A standard 
protocol was applied based on proteinase K digestion, phenol-chloroform separation and 
ethanol precipitation. Good quality DNA was obtained and the quality and concentration of 
the DNA was measured by spectrophotometry.  
 
3.2.2 Array CGH 
The comparative genome hybridisation (CGH) was introduced by Kallioniemi et al in 1992 
and is a molecular cytogenetic technique allowing screening of whole genomes and revealing 
chromosomal regions of gains and losses (125). In Paper II of this thesis, we used the array-
CGH technique, which has developed from the classical metaphase CGH (126, 127). The 
array-CGH was performed at Prof. V. Peter Collins and dr Koichi Ichimura lab at 
Addenbrooke’s Hospital, Cambridge, UK. DNA extracted from tumour samples were 
labelled with red fluorochrome and each tumour sample was co-hybridised wih normal 
reference DNA (labelled green) to the arrays. Prior to hybridisation, the array slides were 
competitively hybridised with Cot-1-DNA to allow blocking of repetitive sequences. The 
arrays consisted in our case of totally 3038 clones: 2555 BAC clones, 477 PAC clones and 6 
cosmids distributed over the entire genome with a mean average distance of 0,97 Mb, printed 
on a glass slide.  The ratio of fluorescence intensity of the tumour to the reference DNA was 
then calculated to measure the copy number changes for a particular location in the genome. 
The ratio in favor of green indicated loss and in favor of red meant excess of tumour DNA, 
hence gain (Figure 9). 
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Figure 9. Schematic illustration of metaphase CGH and array-CGH. The main difference 
concerns the hybridisation target. In metaphase CGH – the chromosomes are spread on slides 
while in array-CGH they are replaced by BAC/PAC clones corresponding to genomic regions 
(adapted by permission of dr Emma Flordal Thelander from her doctoral thesis “Genetic 
Characterisation of Hematological Malignancies with Focus on Mantle Cell Lymphoma”  
2007 (128)) .  
 
The resolution of arrays depends generally on their design, the number of DNA target 
sequences, their individual lengths and the distance between them (129). The resolution can 
be for example increased by using tile path arrays, that are design to leave no gap between the 
clones and the clones are spotted on the arrays in order to overlap each other (129) (Figure 
10). 
The remaining disadvantage of genomic array techniques is their inability to detect 
completely balanced aberrations like inversions, insertions and translocations. However, the 
typically high resolution of genomic arrays, the possibility of fast detection of genomic 
imbalances in archival material, quickly made this method important tool in molecular 
cytogenetics (21). 
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Figure 10. A schematic illustration of different array-CGH approaches and resolutions. 
(adapted by permission of dr Emma Flordal Thelander from her doctoral thesis “Genetic 
Characterisation of Hematological Malignancies with Focus on Mantle Cell Lymphoma”  
2007 (128)). 
 
3.2.3 Taqman DNA copy number analysis 
Taqman DNA copy number analysis is used for a copy number prediction at a specific locus. 
It is a quantitative PCR based Taqman method, that was applied in Paper II in order to 
validate the results of array-CGH. The Taqman DNA copy number analysis present a similar 
approach as real time qPCR. The target and reference primers are labeled with FAM and VIC 
dyes respectively and both are run in a duplex-real time PCR. The reference primer is 
designed to detect genomic sequence with known diploid copy number, which acts as internal 
control. Each reaction is run in triplicates using a qRT-PCR machine.  The number of copies 
of the target gene in each test sample is determined by relative quantification using the 
comparative Ct (ΔΔ Ct) method (130). This method measures the Ct difference (Δ Ct ) 
between target and reference and compares the Δ Ct  of the test probe to a calibrator sample, 
that has two copies of the targeted gene. The copy number of the target is then calculated.  In 
Paper II, we have extracted raw data from RT–PCR by means of Sequence Detection 
Software SDS (Applied Biosystems) and DNA copy number prediction was calculated by 
CopyCaller software (Applied Biosystems).  
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3.2.4 DNA sequencing 
The DNA sequencing technology was introduced in 1977 by Fred Sanger, who in 1980 was 
awarded the Noble Prize for his invention. Originally, the method used modified ddNTPs 
(dideoxonucleotides) lacking 3’-OH group and terminating the DNA strand elongation in 
PCR. That required four reactions run per sample, as one of four ddNTPs (ddATP, ddGTP, 
ddCTP,  ddTTP) was used in each PCR experiment. The classical reaction required a single 
stranded DNA template, a DNA primer, a DNA polymerase, normal dNTPs and one of four 
modified ddNTPs. As the ddNTP would terminate the DNA strand elongation, a PCR 
product consisting of a mixture of DNA fragments with different length was obtained. The 
DNA fragments were then separated by gel electrophoresis and DNA sequence was decoded 
(131). The technology then developed by using various fluorescent dyes in order to separate 
the signals from different bases (dye terminator sequencing), which enabled to run one 
reaction per sample (132, 133). Later the method was improved through utilisation of 
capillary electrophoresis for separation and detection of results in chromatograms as 
individual peaks for each base in the sequence (134). The automated Sanger method is known 
as “first generation”, while the newer methods are called “next generation sequencing” 
(NGS) (135). Sequencing technologies offer a broad variety of methods grouped according to 
the template preparation, sequencing method, imaging and data analysis. The unique and 
specific protocols determine the differences in data output from various platforms.  
In our Paper III, we have used the Illumina platform HiSeq 2000 (San Diago, CA, USA). In 
this method, the procedure starts with the preparation of libraries from DNA or RNA. Then 
the single stranded molecules in the library are hybridised to oligonucleotides attached to a 
glass surface of a flow cell. The complementary strand is synthesised by a polymerase. There 
are now two types of olignoucleotides attached to the surface, one of them available as a free 
end. During the next step called “bridge amplification”, the free end of the newly synthesised 
strand falls over, and attaches to another oligonucleotide forming a single stranded (ss) bridge 
(135). Then, the other complementary strand is synthesised forming a double stranded (ds) 
bridge. The two strands are then denaturated, and the amplification is repeated.  This process 
is called “clustering”. A cluster is a clonally amplified fragment of target DNA, bound to the 
Illumina flow cell. In the end, each cluster of ds DNA is denaturated, with removal of the 
reverse strand, so that only the forward strand is left. In total, about 100-200 million 
molecular clusters are formed, where each cluster corresponds to a single molecule from the 
library (135). During sequencing a primer is hybridised to the forward strand. A reversible 
terminator, that is fluorescently labelled, is bound to each dNTP, and then cleaved to enable 
incorporation to the next base (136).    
3.2.5 Proteomics 
The successful expansion of genetic methods has raised the level of opportunities for studies 
on proteins and this area of interest with the all–embracing name “proteomics” (137). 
Proteins are the crucial elements of cellular machinery, performing tasks in all the biological 
processes. In short, one may say, that life depends on proteins. (138). The crucial role of 
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proteins was recognized early in life sciences. The name “protein” comes from a Greek word 
“proteios”, which means “the first rank” , and was introduced by Berzelius in 1838 pointing 
out the meaning of these molecules (137). It is estimated that more than (numbers vary from 
10,000 to 500,000, with up to 50,000 polypeptide chains) 9000 proteins are involved in a 
various biological functions per nucleated cell (137).  
Moreover, posttranslational modifications, such as phosphorylation, hydroxylation, 
methylation, glycosylation etc) create a large diversity within the proteins. Studying of 
proteins is of great interest and importance, and the popularity of protein analyses including 
mass spectrometry is also increasing. 
There are two main approaches for mass-spectrometry based proteomics, that can be 
described as “top-down” and “bottom-up” analysis (138). In the “top-down” approach, the 
intact proteins are separated by various techniques, e.g. by 2DE, and identified by mass 
spectrometer. The most common example of “top-down” mass spectrometry method is 
matrix-assisted laser desorption/ionization (MALDI).  In the “bottom-up” methods proteins 
are enzymatically digested into peptides using enzymes like trypsin or pepsin, and are in 
solution after chromatography or electrophoretic separation (138).  This peptide mixture is 
then introduced to a mass-spectrometer. An example of “bottom up” method is liquid 
chromatography tandem mass-spectrometry (LS-MS/MS). Both these unique methods have a 
shared mode of analysis, which is mass-spectrometric analysis. In mass-spectrometric 
analysis, the mass-to-charge ratios (m/z) of analysed molecules are obtained. By collecting 
this data, the analysed compounds can be identified by comparison against the standard 
database of molecules with known masses (138). In the whole protein analysis in “top-down” 
proteomics, and in the peptide analysis in “bottom-up” proteomics, each compound is given 
m/z signature detectable by the mass spectrometer. A combination of the different techniques 
creates additional possibilities for proteomic analysis.  
3.2.5.1 MALDI-TOF MS  
Matrix associated laser desorption/ionization (MALDI) is an ionization mass-spectrometry 
based method, in which the studied peptides or proteins are ionized by a laser impulse, and 
then generated ions are measured. MALDI-TOF-MS (Matrix associated laser 
desorption/ionization time of flight mass spectrometry) was applied for protein identification 
in Paper IV.  
First the proteins are separated through a two dimensional electrophoresis (2-DE) in 
polyacrylamide gel. The proteins are digested and separated by their isoelectric point  (first 
dimension) followed by separation according to molecular mass (second dimension). The 
gels with protein spots are visualized by silver stain of fluorescent dyes. Stained 2-DE gels 
are scanned and the staining intensities of all protein spots are analysed by an image analysis 
software. By applying multivariate statistics analysis, the protein spots for identification by 
MS are selected. The selected proteins spots are then excised, destained, and undergo trypsin 
digestion. The generated mixture of peptides is then embedded in a matrix compound, that 
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had the capability to absorb the laser energy and then ionise the molecules. The samples are 
loaded to a mass spectrometer, where the peptides are ionised under the effect of laser beam. 
The ions are separated according to their mass-to-charge ration, typically by accelerating 
them in an electric or magnetic field, and are measured by a detector capable of detecting 
charged particles, such as an electron multiplier. The results are in form of spectra of detected 
ions. The obtained data are then matched against established databases in order to identify 
corresponding proteins matching up the theoretical peptide masses with experimentally 
observed.  
3.2.5.2 SELDI-TOF-MS and LC MS/MS 
Surface enhanced laser desorption/ionisation time of flight MS  (SELDI-TOF-MS) differs 
from the MALDI-TOF-MS by a main distinction, that in the SELDI-TOF the tested proteins 
are applied on a chip array, which contains different chemicals associated with various 
properties (hydrophobic, hydrophilic etc). Based on these distinctive properties, the analytes 
are selected through bounding to a chip surface. All other undesired components are then 
washed away, which increases the volume of low-abundant molecules in the analysed 
sample, but on the other hand some information may be missed due to decreased variety of 
the compounds. The further procedures, including matrix application, ionization, detection of 
ions, and m/z analysis is similar to MALDI (139).  
Liquid chromatography tandem mass spectrometry (LS-MS/MS) is used to identify proteins 
by physical separation of peptides using isoelectrophocusing, followed by analysis by mass 
spectrometry (139). Firstly, all the proteins are digested using trypsin, and then labeled with 
isotops in order to enable quantification. The labelled molecules are then pooled in a tube, 
undergo isoelectric focusing in an immobilized pH gradient gel, and are analysed by LC-
MS/MS, where they undergo the electrospray ionization and peptide fragmentation. The 
analysis leads to information on peptide’s amino acid sequence, and various software tools 
are available for protein identification and peptide quantification.  
Facing the rapid development of MS techniques, some may suggest, that 2DE-method is no 
longer the method of choice for proteomic analysis. However, at the same time, as 
recognition of issues related to newer shotgun-MS methods grow, there is the fresh look at 
maturity and strengths of 2DE-MS as genuine analytical method (140). 2DE-MS strength 
depends on the fact, that it allows the analysis of intact proteins in a single run, enabling the 
simultaneous characterization of total protein compartment consisted of thousands of 
proteins, including isoforms and post-translational modifications (140).  
 
3.2.6 Immunohistochemistry 
Immunohistochemistry (IHC) is an analytical method used to detect the presence or absence 
as well as localisation of proteins. IHC is based on the binding of antibody to a specific 
antigen in cells or tissues (141). IHC applies commonly to FFPE sections, but can also be 
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used on fresh frozen tissue and cytological material. According to classical IHC procedure 
used on FFPE sections, tissue is deparaffinised in 100% xylene, followed by rehydration in 
graded series of ethanol and water solution. The antigen retrieval is performed by incubation 
in citrate buffer in order to bind calcium ions, that could interfere during binding of primary 
antibody to the antigen. Antigen retrieval is performed at high temperature  (95-99°C) for the 
restoration (retrieval) of the “formalin modified” antigen molecular structure. After this step, 
the sections are pre-treated with hydrogen peroxide, that blocks an endogenous peroxidase, 
that otherwise may cause a non-specific background staining. Non-specific binding of 
primary and secondary antibodies is blocked by bovine serum albumin. The primary antibody 
is then applied on a tissue, where it binds to a target epitope. This step is followed by 
application of secondary antibody, which is biotinylated and has affinity to avidin . The ABC 
(avidin/biotin complex) solution is then added and binds to the secondary antibody through 
reaction between biotin (on the secondary antibody) and avidin. Avidin components interact 
with biotinylated horseradish peroxidase, that increases the intensity of the signal after 
addition of a chromogen substrate. The most commonly used chromogen substrate is 
diaminobenzidine (DAB), which gives finally brown staining as a final result of the above 
described procedures. The finishing steps include dehydration of tissue sections in increasing 
grade of ethanol concentrations and 100% xylene followed by counterstain with hematoxylin. 
In our Papers I, II and IV we performed immunohistochemistry according to the above 
described principles, using method developed, automated and optimised by Bond Max 
System (Leica, Newcastle Upon Tyne, UK).   
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4 RESULTS AND DISCUSSION  
4.1 PAPER I: HAX-1 EXPRESSION IN B-CELL LYMPHOMA 
In our first work, performed in collaboration with Prof. Bengt Fadeel group (Institute of 
Environmental Medicine, Molecular Toxicology, Karolinska Institutet), we have investigated 
the expression of the HAX-1 gene in human B-cells lymphoma on mRNA and protein level. 
HAX-1, which is a multifunctional protein involved in apoptosis and cell migration, has 
previously been shown to be involved in different cancer type, but has never been studied in 
hematological malignancies (142). In paper I, the HAX1 expression was first evaluated on 
mRNA level, through search of in two public databases: the In Silico transcriptomics (IST) 
database containing data from 9783 Affymetrix gene expression analysis from 43 normal 
tissues, 68 cancer types and 64 other entities and the Human gene expression map composed 
of data extracted from 5372 samples and 369 cell types. The results of the IST search showed 
a high level of HAX-1 expression in hematological malignancies, especially plasma cells 
neoplasm (plasma cell leukemia and myeloma) as well as B-cell lymphomas. The Human 
gene expression map search showed HAX-1 overexpression in anaplastic large T-cell 
lymphoma. Next, we investigated the HAX-1 protein expression detected by IHC in a panel 
of B-cell derived neoplasms, that consisted of 50 B-cell lymphomas (including B-CLL, 
immunocytoma, MALT lymphoma, MCL, FL, DLBCL of GC and non GC type, Burkitt 
lymphoma and Hodgkin lymphoma). The FL samples were selected based on the previous 
publications from members of the same group investigating HAX1 mRNA expression on 
number of FL cases by microarray analysis (122). The results of IHC evaluation of HAX-1 
protein expression were compared with expression of anti-apoptotic protein Bcl-2 and 
proliferation measured in Ki67 staining. Our IHC results showed a negative correlation 
between the HAX-1 expression and Bcl-2 expression in various types of B-cells lymphoma. 
That may suggest the role of HAX-1 as a Bcl-2 homolog, compensating for low Bcl-2 
expression in these tumours. Moreover, we could also observe a positive association between 
HAX1 expression and Ki67 suggesting that there may be other functions involving HAX-1 
beyond the anti-apoptotic effect.  Interestingly, the gain and amplification of 1q21.3 region 
being locus of HAX-1 gene has been reported in aggressive tumours including transformed 
DLBCL described in our Paper II (143) .   
 
4.2 PAPER II: TRANSFORMED DLBCL FROM FL 
Transformation of FL to DLBCL is a common event associated with poor prognosis and 
response to treatment. Hence, there is a need for molecular markers of transformation that 
would enable prediction of this event and adjustment of treatment. In studies on genomic 
copy number alterations, gains involving +1q, +2p, +3q, +7, +8q, +12, +17q, +18q, +X and 
lost of -1p36, -4q, -6q, -8p, -13q and -17p were reported as associated with transformation 
(120, 123, 144-146). Several genes have been postulated to be involved in the transformation 
FL to DLBCL, including TP53, MYC, REL, BCL-2 and MYD88 (147-151). The previous 
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reports have also described gains of the 2p15-16 region detected by array-CGH. The REL 
gene located in this region has been discussed as a potential driver for the transformation 
process (144).  
In our Paper II project, performed in collaboration with Prof V. Peter Collins and dr Koichi 
Ichimura (Department of Pathology, Addenbrooke’s Hospital, Cambridge, UK), we have 
studied 81 tumours from 60 patients (29 dnDLBCL, 31 tDLBCL, and 21 antecedent FL) 
regarding chromosomal copy number alterations using array-CGH. Paired tumour samples 
were obtained from 15 patients and within this group 3 tumour sets consisted of more than 
two consecutive samples, allowing us to follow specific genetic changes during the 
progression, and before and after transformation. Half of the tumours were previously 
outlined by metaphase CGH by the members of our group (123). In our study, we have 
observed, that the DLBCLs showed a higher number of imbalances as compared to FL, and 
tDBLCL as compared to dnDLBCL, indicating that in particular the tDLBCL tumours are 
more instable cytogenetically. This observation has also been reported in previous studies 
(144, 152).   
In our attempt to outline the chromosomal alterations of importance for the transformation, 
we have found, that the 2p15-16 region encompassing, among others, the REL, BCL11A, 
PEX13, USP34, XPO1, COMMD1 and OTX1 genes, was the only alteration that showed a 
high level amplification detected. We have observed, that a gain/amplification of this region 
was more common in tDLBCL than dnDLBCL (p<0.001). Moreover, the amplification of 
2p15-16 region could also be seen in FL prior to transformation, and in first tDLBCL directly 
after transformation, pointing out the possible role of this alteration in the transformation 
process. We have also performed quantitative real time PCR on the selected, previously 
mentioned genes within 2p15-16 region, and could observe a higher level of amplification of 
REL, USP34, COMMD1 genes (all of them involved in NF-κB pathway) indicating their 
potential role as drivers for transformation.  
Moreover, we could demonstrate that 17q21.33 amplification was exclusively found in 
tDLBCL as compared to FL and dnDLBCL (p<0.04), and could be associated with late phase 
of transformation. Likewise, a higher number of losses at 6q16.3, 9p and 14q as well as gains 
of 6p were found as late events in FL prior to transformation suggesting the potential role of 
the genes located in these regions in the peri-transformation phase of transformation.  
 
4.3 PAPER III GENETIC ALTERATIONS DURING TRANSFORMATION 
Our third project, related to Paper II, was performed in collaboration with Prof. Qiang Pan-
Hammarström’s group (Division of Clinical Immunology, Karolinska Institutet).  In this 
study, the whole exome sequencing (WES) was performed on paired tumours (FL-tDLBCL) 
obtained from four patients. One of the patients (patient 4, P4) was presented with 4 
consecutive FL and 2 sequential DLBCL tumours. Studies of these samples allowed us to 
follow the changes acquired during progression and transformation of the disease.  Three of 
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the patients (including P4) have been previously characterised by array-CGH in our second 
project. We could thus compare results of the WES experiment with the array-CGH data.  As 
a result, we found an overlap between the CNV pattern and the mutation landscape. 
Moreover, the pathway analysis has shown that pathways (and genes) altered in FL included 
apoptosis (IRAK2, CSF2RB), and Wnt signaling (LPR5, PLCB4), while pathways affected in 
DLBCL comprised B-cell receptor pathway (VAV3, CARD11, PLCG2). Interestingly, the 
multi-sample case has shown that MLL2 and MEFB2 were the only recurrently mutated 
genes, and notably, different mutations were detected in these genes in the two early FLs as 
compared to the six later tumours (FLs and tDLBCLs), corresponding to progressed and 
transformed disease. We have also investigated the aspect of transformation. For this purpose, 
we have looked at mutations overlapping the CNV, and present in FL prior and DL right after 
transformation. As a result, we could suggest, that genes CHD4, NPY5R, PPP1R15B as well 
as DOCK4 and MROH5 may be of interest in the context of transformation process.  
To conclude, in Paper III, we have shown the strength of integrated analysis combining the 
mutation pattern identified by WES with the CNV –profile detected by array-CGH. This 
integrated approach allows outlining of genetic alterations, that may be of importance for the 
progression and transformation. Also, it strengthens the likelihood, that these alterations are 
of the somatic origin of these alterations, even in the situations where no normal tissue 
control is available for comparison.  Moreover, we could demonstrate, that the clonal 
evolution of FL, leading to progression and transformation to DLBCL, occurs according to 
the branching rather than the linear model (Figure 11). 
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Figure  11. “Evolutionary tree” illustrating clonal evolution of the lymphoma in patient 4. 
The arrows indicate copy number changes: acquired alterations are listed above the branch 
and lost below the branch. The number of shared and acquired mutations are shown within 
the branches (adapted from Paper III, Figure 2B).   
 
4.4 PAPER IV PROTEOMIC PROFILING OF DLBCL 
Since the major breakthrough of GEP studies published by Alizadeh et al in 2000, that 
identified molecular subtypes of DLBCL (GC, ABC and unclassified) associated with 
different genetic, biological and clinical features, there has been a need to translate these 
results into diagnostic routine and clinical practice (55). The OMICs technologies offer a vast 
variety of methods, which can be used in search for biomarkers, that could be applied as 
diagnostic and prognostic tools as well as therapeutic targets. Despite the fact, that proteomic 
profiling is a well-established method, which allows studying a whole proteome of intact 
proteins in cells and tissues, little has been reported about protein expression profiles in 
various DLBCL subtypes. The groups of Deeb and Ruetschi have independently, recently, 
presented a super-SILAC based approaches leading to a 55-protein and 87-proteins signature 
respectively, which may allow to discriminate different DLBCL subtypes (153-155). We 
have performed this study in order to focus on the proteome profiling of DLBCL subgroups 
  45 
(non-GC and GC) on the level of intact proteins.  31 DLBCL tumours were studied (16 non-
GC and 15 GC type), of which 6 samples (3 non-GC and 3 GC) were used for proteomic 
based analysis. As the result of proteome profiling we found 300 protein spots differentially 
expressed between the non-GC and GC type of DLBCL. During mass-spectrometry analysis 
we identified 91 proteins, that were present exclusively in non-GC but not in the GC type of 
DLBCL. We then performed systemic analysis of identified proteins that led to creation of 19 
subnetworks. The subnetworks represented proteins and genes involved in cell proliferation, 
cell death, cell cycle regulation, NF-ĸB pathway, MAPK signaling, PI3 kinase pathway, Wnt 
signaling, B-cell receptor signaling, proteasomal activity, p53 pathway and many others. At 
the end, we selected three proteins: BiP (immunoglobulin heavy chain binding protein), 
Hsp90 (heat shock protein 90) and cyclin B2 for validation by IHC. BiP and Hsp90 are 
proteins involved in the NF-κB pathway, while cyclin B2 is involved in the cell cycle 
regulation (Figure 12 and 13). We showed that BiP and Hsp90 tend to be over-expressed in 
the non-GC type of DLBCL. Although positive expression of BiP was observed in less than 
the half of the DLBCL cases in our study, a positive Hsp90 expression was seen in almost all 
the cases. Likewise, the overexpression of cyclinB2 was seen in the majority of the cases with 
more than the half showing moderate staining. Although cyclin B2 was shown to be an 
adverse prognostic markers in various cancer types, it has not been previously studied in a 
context of lymphoma. Our findings suggest the potential clinical relevance of these proteins 
and also implicate the need for further proteomic studies in this field.  
 
Figure 12. Schematic illustration of functions and relationship of the studied proteins. BiP 
(GRP78) is a ER chaperon. BiP is stabilised by Hsp90. Normally, BiP protects cells from 
accumulated unfolded proteins. In tumours, BiP act as a inhibitor of apoptosis. Cyclin B2 is a 
cell cycle protein, that has been shown to be overexpressed in various tumours.  These 
proteins can potentially be affected by inhibitory treatment. (Modified after Gutierrez et al 
2014 (156)).  
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Figure 13. Schematic illustration of regulation of NF-κB pathway by Hsp90. The ability of 
Hsp90 to regulate cell survival depend most of all of the level of IKK complex. The Hsp90 is 
forming a complex with Cdc37, which is a co-chaperone and then bind to IKK complex via 
interaction with regulatory subunit IKKγ (NEMO) and IKKβ. This Hsp90 mediated IKK –
dependent mechanism seems to be crucial for NF-κB activation leading to cell survival.  
(Modified by Beere 2000 (157)).  
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5 CONCLUSIONS  
 
• Several genomic events are involved in the transformation of FL to tDLBCL, and 
array-CGH (detecting CNVs) and WES (identyfying mutations) give complemetary 
information on the pathobiology of this process. Mutations detected within CNVs are 
more likely to be of somatic origin and could be regarded as of tumourigenetic 
importance, even without the presence of a normal tissue for comparison.  
 
• The 2p15-16.1 gain/amplification is involved in the transformation from FL to 
tDLBCL, and is associated with worse prognosis. If noted in FL, this aberration has a 
potential to serve as molecular marker associated with risk for transformation. 
 
• The 2p15-16.1  region encompasses several genes, such as REL, BCL11A, PEX13, 
USP34, COMMD-1, XPO-1 and OTX-1, of which some are involved in     NF-κB 
pathway, underlying its importance as a target for personalised therapies. 
 
• 17q21-23 was gained only in tDLBCL, and was not found in FL or dnDLBCL, and 
could therefore be considered a marker for tDLBCL. 
 
• Tumour progression of FL and its transformation to tDLBCL occurs rather according 
to the branching model than the linear one. 
 
• The protein profiles of non-GC and GC types of DLBCL identified at least 91 
proteins differentially expressed between these two groups. These proteins were 
involved in functional networks representing, among others: the cell proliferation, cell 
death, cell cycle regulation, NF-ĸB pathway, MAPK signalling, PI3 kinase pathway, 
Wnt signalling, B-cell receptor signalling, proteasomal activity, and p53 pathway. 
 
• BiP and Hsp90, involved in NF-ĸB pathway, as well as Cyclin B2 showed an 
increased expression in DLBCL, and tended to be related to the non-GC type of 
DLBCL. These proteins could therefore be a potential clinical markers.  
 
• HAX-1 shows a positive correlation with Ki67 and an inverse correlation with Bcl2, 
which suggests its role as Bcl-2 homolog. Furhermore, HAX-1 shows a variable 
expression on protein and transcript level among different subtypes of B-cell 
lymphomas.  
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6 FUTURE PROSPECTS  
 
The challenge of the next decade will be to bring research discoveries to a clinical practice. It 
must be done in an efficient and practical way, and will depend on collaborations among 
institutions and professionals of various disciplines (158). 
 
First, there is a need of an integrated approach to diagnostics that will combine the data 
obtained from various molecular methods and allow the selection of the most promising 
biomarkers for a specific clinical application and individual patients. Second, these 
biomarkers will need to be validated on e.g. drug test assays for a routine clinical approach. 
The third step will be combining drugs for the best effect, optimal dosing, and least toxicities 
for the particular individual patient.  
 
Cancer research is a very dynamic field but its success will be measured by the ability to 
combine the scientific data into practical approach that may be used in the every day clinical 
practice. They will need a cooperation between research laboratories, clinical diagnostic 
laboratories and new generation clinical trials, that would allow combination of different 
drugs with various therapeutic modalities. That will be only possible with open collaborations 
and a pragmatic approach involving scientists, clinical laboratory medicine specialists and 
clinicians.  
 
The pathologist in a multidisciplinary team has a critical and vital role for the choice of 
treatment. Based on the deep understanding of disease and professional expertise, the 
pathologists provides the clinician not only with the diagnosis, but also with information 
about individual characteristics of the disease, its histopathological and molecular profile, 
giving an important perspective in a team considering a patients’s case.  
 
Personally, I believe in a close collaboration between Clinical Departments of Hematology 
and Oncology, Clinical Laboratories and large Research Centers, integrating molecular 
medicine, diagnostics, research technology and biobanking infrastructure with clinics, 
enabling the adaptation of personalised medicine in health care. The examples of centers 
successfully creating such platforms are inspiring and give a promise for future of Karolinska 
University Hospital, Karolinska Institute and Sci-Life Laboratory. The optimal goal would be 
a collaboration with other centers on the national and international level.   
 
Looking ahead, we have also started a collaboration with colleagues from University of Oslo, 
Oslo University Hospital as well as University of Toronto, planning further investigation of 
potential clinical implications of proteomic markers described in this thesis in a larger cohort 
of patients. We have performed further experiments and are going to correlate the results with 
clinical data together with our colleagues in Norway and Canada.  
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